Drugs / Bromazepam
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06993662 | Jun 2025 → Dec 2027 expected | anxiety, bipolar disorder, depressive disorder, obsessive-compulsive disorder +3 | Rakitzi, Stavroula | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04410536 Background | Jun 2020 → Dec 2021 | migraine disorder | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bromazepam | “bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day” NCT04410536 ↗ |
| Known as | Bromazepam civ | ChEMBL registry synonym — accepted as the source's own label CHEMBL277062 ↗ |
| Known as | Lectopam | ChEMBL registry synonym — accepted as the source's own label CHEMBL277062 ↗ |
| Known as | Lexatin | ChEMBL registry synonym — accepted as the source's own label CHEMBL277062 ↗ |
| Known as | Lexotan | ChEMBL registry synonym — accepted as the source's own label CHEMBL277062 ↗ |
| Known as | lexotanil | “The combination of pharmacotherapy (anxiolytics (Tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI)) and individual cognitive behavioral psychotherapy by anxiety...” NCT06993662 ↗ |
| Known as | NSC-140669 | ChEMBL registry synonym — accepted as the source's own label CHEMBL277062 ↗ |
| Known as | RO 5-3350 | ChEMBL registry synonym — accepted as the source's own label CHEMBL277062 ↗ |
| Action | Activate | “GABA receptor alpha-2 subunit positive allosteric modulator” CHEMBL277062 ↗ |
| Modality | Small molecule | — CHEMBL277062 ↗ |
| Route | Oral | “oral administration of a bridge therapy to reduce the withdrawal symptoms and rebound headache (prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days,...” NCT04410536 ↗ |
| Target | GABRA2 | “GABA receptor alpha-2 subunit positive allosteric modulator” CHEMBL277062 ↗ |